Government takes bold step towards reproductive health equity

Pharma News: Following a Senate inquiry into universal access to reproductive healthcare, the Federal Assistant Minister for Health and Aged Care, Ged Kearney, has announced a significant breakthrough. The Therapeutic Goods Administration (TGA) will be removing several restrictions regarding the prescribing and dispensing of medical abortion pills, mifepristone and misoprostol.

This historic decision comes as a welcome relief to advocates of reproductive rights across the country. Professor Danielle Mazza, Head of General Practice at Monash University, Chief Investigator and Director of SPHERE Centre of Research Excellence in Women’s Sexual and Reproductive Health in Primary Care and Australian National Women’s Health Advisory Council special adviser shared her thoughts on the matter.

“This very welcome decision aims to destigmatise and increase access to abortion, and bring Australia into line with countries such as Canada, which in 2017 completely deregulated mifepristone. This move not only provides evidence of continued safety but also demonstrates a marked increase in the number of providers,” Professor Mazza stated.

The previous restrictive arrangements, in place since the availability of medical abortion in Australia in 2012, caused significant access problems, particularly for women with limited incomes or those residing in rural and regional areas.

Under the old regulations, General Practitioners (GPs) were required to undergo mandatory training and register before being allowed to provide the abortion pill, with re-registration every three years. As a result, only about 10% of GPs in Australia were registered to prescribe. However, with this new development, the rights of women across the country will be better protected.

Expressing her admiration for the Minister’s commitment to achieving this goal, Professor Mazza added, “Wherever they live, women have the right to a safe and easy abortion, and I congratulate the Minister for her commitment to achieving this goal.”

Minister Kearney said “Our government has no higher priority than strengthening primary care and welcome the changes that allow these trusted and highly skilled providers to provide care within their scope of practice.”

The Australian College of Nursing (ACN) also commended the decision, highlighting its potential to improve healthcare accessibility for women, particularly those residing in rural and remote communities. CEO Adjunct Professor Kylie Ward emphasised the importance of recognising the scope of practice of Nurse Practitioners and the positive impact it can have on women’s access to crucial health information and services.

“This decision makes healthcare for women safer, more accessible, more equitable, and removes red tape. Medical terminations are safer and more affordable than surgical interventions,” Professor Ward explained.

“Nurse Practitioners are readily available at all stages of the medical termination process for women. They can provide information and education prior to the termination, monitor the woman after the treatment, and offer ongoing comfort and care. They are there every step of the way.”

Furthermore, the decision has garnered support from the Pharmaceutical Society of Australia (PSA). The National President, Dr Fei Sim, hailed the move as a significant step forward for women’s healthcare access. By acknowledging pharmacists as medicine experts and recognising their role in dispensing and counselling patients on the use of abortion pills, the TGA’s decision aligns with international best practices.

As the changes take effect from August 1, 2023, the decision to ease restrictions on abortion pills represents a landmark moment in Australia’s pursuit of comprehensive and accessible reproductive healthcare for all.

In reimagining healthcare, Health Industry Hub^TM is the ONLY one-stop-hub uniting the diversity of Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change. The exclusive leadership and influencer podcasts and vodcasts offer unparalleled insights and add immense value to our breaking news coverage.

The Health Industry Hub^TM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.